CR10627A - Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 - Google Patents
Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4Info
- Publication number
- CR10627A CR10627A CR10627A CR10627A CR10627A CR 10627 A CR10627 A CR 10627A CR 10627 A CR10627 A CR 10627A CR 10627 A CR10627 A CR 10627A CR 10627 A CR10627 A CR 10627A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- dii4
- therapeutic methods
- ocular disorders
- dii4 antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un metodo terapeutico para el tratamiento de trastornos isquemicos o vasculares mediante la administracion de un agente capaz de inhibir la actividad del ligando 4 similar a delta (DII4) humano en un sujeto que lo necesita. Preferiblemente, el agente es un anticuerpo anti-DII4 o fragmento de anticuerpo capaz de inhibir la union de DII4 a un receptor Notch.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83600306P | 2006-08-07 | 2006-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10627A true CR10627A (es) | 2009-04-14 |
Family
ID=38904599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10627A CR10627A (es) | 2006-08-07 | 2009-02-20 | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 |
Country Status (33)
Country | Link |
---|---|
US (1) | US20080181893A1 (es) |
EP (1) | EP2054082B1 (es) |
JP (1) | JP5529536B2 (es) |
KR (1) | KR101497355B1 (es) |
CN (1) | CN101500605B (es) |
AU (1) | AU2007281916B2 (es) |
BR (1) | BRPI0716424B8 (es) |
CA (1) | CA2660235C (es) |
CO (1) | CO6150190A2 (es) |
CR (1) | CR10627A (es) |
DK (1) | DK2054082T3 (es) |
ES (1) | ES2398253T3 (es) |
GT (1) | GT200900029A (es) |
HK (1) | HK1137339A1 (es) |
HR (1) | HRP20130271T1 (es) |
IL (1) | IL196612A (es) |
MA (1) | MA30667B1 (es) |
ME (1) | ME00591A (es) |
MX (1) | MX2009000674A (es) |
MY (1) | MY150092A (es) |
NO (1) | NO341857B1 (es) |
NZ (1) | NZ574794A (es) |
PL (1) | PL2054082T3 (es) |
PT (1) | PT2054082E (es) |
RS (1) | RS52685B (es) |
RU (1) | RU2429876C2 (es) |
SG (1) | SG174033A1 (es) |
SI (1) | SI2054082T1 (es) |
SV (1) | SV2009003161A (es) |
TN (1) | TN2009000036A1 (es) |
UA (1) | UA95304C2 (es) |
WO (1) | WO2008019144A2 (es) |
ZA (1) | ZA200900337B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2664738C (en) | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
CA2734694A1 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
EP2927244A1 (en) * | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
WO2011008641A1 (en) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Methids of modulating angiogenesis and treatment of angiogenesis-related diseases |
US8623358B2 (en) | 2009-08-29 | 2014-01-07 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
HUE029661T2 (en) * | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
CN107722122B (zh) | 2011-09-23 | 2022-05-27 | 昂考梅德药品有限公司 | Vegf/dll4结合剂及其应用 |
US20150368329A1 (en) * | 2012-10-15 | 2015-12-24 | Oncomed Pharmaceuticals, Inc. | Methods of Treating Ocular Diseases |
WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
JP6967003B2 (ja) | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ 5 インコーポレイテッド | がんの処置のための方法および組成物 |
WO2018094267A1 (en) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Novel methods to enhance microvascular engraftment of bioengineered and primary tissues |
WO2023063842A1 (ru) | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
WO2007028110A2 (en) * | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
EP2029159A2 (en) * | 2006-06-06 | 2009-03-04 | Genentech, Inc. | Compositions and methods for modulating vascular development |
-
2007
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/en active Application Filing
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active IP Right Grant
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 RS RS20130078A patent/RS52685B/en unknown
- 2007-08-07 EP EP07811137A patent/EP2054082B1/en active Active
- 2007-08-07 CA CA2660235A patent/CA2660235C/en active Active
- 2007-08-07 ME MEP-31/09A patent/ME00591A/xx unknown
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
-
2010
- 2010-01-29 HK HK10101051.2A patent/HK1137339A1/xx unknown
-
2013
- 2013-03-25 HR HRP20130271TT patent/HRP20130271T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
MX2020007092A (es) | Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos. | |
BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
SV2006002342A (es) | Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida | |
UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
CY1111478T1 (el) | Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης | |
AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
CL2008002110A1 (es) | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr119 para administrar un compuesto derivado de piridinona y opcionalmente un agente terapeutico opcional para tratar diabetes mellitus. | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
JO2576B1 (en) | Antibodies | |
EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
BRPI0517963A2 (pt) | piridinureas antralinamidas como inibidores de receptores de cinases do fator de crescimento endotelial vascular | |
ECSP099556A (es) | Nuevos métodos | |
ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
MX366685B (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
DK1869185T3 (da) | Konjugat med P21-protein til kræftbehandling |